Endocyte Receives Consensus Rating of “Buy” from Brokerages (NASDAQ:ECYT)
Shares of Endocyte (NASDAQ:ECYT) have been given an average recommendation of “Buy” by the ten ratings firms that are covering the stock, Analyst RN reports. Three investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $26.17.
A number of research firms have recently commented on ECYT. Analysts at Chardan Capital reiterated a “buy” rating on shares of Endocyte in a research note on Wednesday, July 30th. Separately, analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock.
Endocyte (NASDAQ:ECYT) opened at 6.41 on Thursday. Endocyte has a one year low of $5.91 and a one year high of $33.70. The stock has a 50-day moving average of $6.45 and a 200-day moving average of $11.22. The company has a market cap of $266.3 million and a price-to-earnings ratio of 18.13.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.42. The company had revenue of $49.17 million for the quarter, compared to the consensus estimate of $26.62 million. The company’s revenue for the quarter was up 198.4% on a year-over-year basis. Analysts expect that Endocyte will post $-0.08 EPS for the current fiscal year.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.